Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioRestorative Therapies Inc BRTX

Healthcare Biotechnology
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured... see more

Recent & Breaking News (NDAQ:BRTX)

BioRestorative Therapies Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

GlobeNewswire June 30, 2022

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

GlobeNewswire June 22, 2022

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

GlobeNewswire June 13, 2022

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

GlobeNewswire April 29, 2022

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

GlobeNewswire April 18, 2022

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

GlobeNewswire April 4, 2022

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

GlobeNewswire March 10, 2022

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

GlobeNewswire February 16, 2022

BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease - Site Selection Underway

GlobeNewswire February 7, 2022

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

GlobeNewswire February 7, 2022

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

GlobeNewswire February 2, 2022

BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine

GlobeNewswire January 26, 2022

BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

GlobeNewswire January 11, 2022

BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 6, 2022

BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells

GlobeNewswire January 4, 2022

BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

GlobeNewswire December 21, 2021

BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show

GlobeNewswire December 21, 2021

BioRestorative Therapies, Inc. Releases Year-End Message

GlobeNewswire December 20, 2021

BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

GlobeNewswire December 2, 2021

BioRestorative Therapies Enters into Letter of Intent with PRC Clinical

GlobeNewswire November 19, 2021